In a report released yesterday, Sean Laaman from Morgan Stanley maintained a Buy rating on Disc Medicine, with a price target of $85.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors that highlight Disc Medicine’s promising future. The company is focused on developing treatments for hematological disorders, with significant potential seen in its lead product candidates, bitopertin and DISC-0974. The anticipated NDA submission for bitopertin in the second half of 2025, along with the expected data for DISC-0974, positions the company for substantial growth.
Laaman’s analysis includes a detailed evaluation of the commercial opportunities for these drugs. For bitopertin, a 2026 launch is projected with peak U.S. sales of approximately $1.3 billion, adjusted for risk. DISC-0974 is also expected to contribute significantly, with projected peak sales in anemia of MF and CKD. Additionally, ongoing studies for other indications could provide further upside to the company’s valuation. These factors collectively support the Buy rating with a price target of $85.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $118.00 price target.